EJU.F - Aethlon Medical, Inc.
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.3100 |
| Open | 0.3140 |
| Bid | 0.3150 x N/A |
| Ask | 0.3250 x N/A |
| Day's Range | 0.3140 - 0.3150 |
| 52 Week Range | 0.2291 - 2.4900 |
| Volume | |
| Avg. Volume | 214 |
| Market Cap | 7.303M |
| Beta (5Y Monthly) | 1.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7100 |
| Earnings Date | Jun 26, 2023 - Jun 30, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.33 |
Fair Value
Related Research
Zacks Small Cap ResearchAEMD: Maximizing R&D Spending to Facilitate Clinical Efforts, Advance Hemopurifier
By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Maximizing R&D spending … Aethlon Medical (NASDAQ:AEMD) has implemented several recent initiatives to maximize its R&D spending in order to advance its lead product, medical device the Aethlon Hemopurifier®, through clinical studies towards obtaining regulatory approval and commercialization. The company’s current focus for
PR NewswireAethlon Medical to Present at the 13th Annual LD Micro Invitational
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, today announced that Guy Cipriani, Senior Vice President and Chief Business Officer, and James Frakes, Chief Financial Officer, will present a company overview at the 13th Annual LD Micro Invitational on Wednesday, June 7, 2023, at 1:30 PM PT.
PR NewswireAethlon Medical Receives Ethics Board Approval to Add Second Site to its Ongoing Clinical Trial of its Hemopurifier® to Treat Severe COVID-19 in India
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced that it has received Ethics Review Board (ERB) approval from the Maulana Azad Medical College (MAMC), for a second site for its ongoing clinical trial of Aethlon's Hemopurifier® to treat severe COVID-19 in India.
Simply Wall St.Aethlon Medical Third Quarter 2023 Earnings: US$0.12 loss per share (vs US$0.16 loss in 3Q 2022)
Aethlon Medical ( NASDAQ:AEMD ) Third Quarter 2023 Results Key Financial Results Net loss: US$2.85m (loss widened by...
- Simply Wall St.
Analysts Expect Aethlon Medical, Inc. (NASDAQ:AEMD) To Breakeven Soon
With the business potentially at an important milestone, we thought we'd take a closer look at Aethlon Medical, Inc.'s...
Zacks Small Cap ResearchAEMD: New CRO to Help Advance Studies; Expanded Team to Facilitate Efforts
By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT New CRO to facilitate study of the Hemopurifier® in a range of cancers To advance its medical device, the HemoPurifier®, through clinical studies towards potential regulatory approval and commercialization, Aethlon Medical’s (NASDAQ:AEMD) has launched several recent initiatives. Among other steps, the company has: ▪ Embarked on launching
Insider MonkeyAethlon Medical, Inc. (NASDAQ:AEMD) Q3 2023 Earnings Call Transcript
Aethlon Medical, Inc. (NASDAQ:AEMD) Q3 2023 Earnings Call Transcript February 13, 2023 Operator: Good day, and welcome to the Aethlon Medical Third Quarter Fiscal 2023 Earnings and Corporate Update Call. All participants will be in listen-only mode. After today’s presentation, there will be an opportunity to ask questions. Please note, this event is being recorded. […]
PR NewswireAethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update
Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2022 and provided an update on recent developments.
PR NewswireAethlon Medical to Present at Sequire Biotechnology Conference on February 2nd, 2023
Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, announced today that it will be presenting virtually at the upcoming Sequire Biotechnology Conference on Thursday, February 2nd, at 10:00 AM ET. Steven LaRosa, M.D., Chief Medical Officer and Chief Scientific Officer of Aethlon Medical, will be giving the presentation.
PR NewswireAethlon Medical Announces Contract with NAMSA to Advance Hemopurifier Clinical Programs in Cancer
Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today announced that it has entered into an agreement with NAMSA, a world leading MedTech Contract Research Organization (CRO) offering global end-to-end development services to oversee the company's clinical trials investigating the Hemopurifier, Aethlon's immunotherapeutic device , for oncology indications.
- Zacks Small Cap Research
AEMD: Hemopurifier Hemopurifier To Be Studied in a Variety of Solid Tumors
By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Studying the Hemopurifier in a range of cancers Aethlon Medical’s (NASDAQ:AEMD) provided a business update. AEMD has been working to launch a blanket oncology trial to study the impact of the Hemopurifier on a variety of cancerous tumors. The company’s goal is to build its database in oncology to help with the development of the
PR NewswireAethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its second quarter ended September 30, 2022 and provided an update on recent developments.
PR NewswireAethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2022
Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its second quarter ended September 30, 2022, at 4:15 p.m. EST on Monday, November 14, 2022.
GlobeNewswireLife Sciences Virtual Investor Conference Agenda Announced for September 15th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15th. Individual investors, institutional investors, advisors, and analysts are invited to attend this virtual event showcasing live executive presentations from companies
PR NewswireAethlon Medical to Present at Two Investor Conferences in September
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, today announced that it will be presenting at two investor conferences in September. These include the H.C. Wainwright 24th Annual Global Investment Conference, being held virtually and in New York from Sept. 12-14, 2022, and the Life Sciences Investor Forum, being held virtually on Sept. 15, 2022. At both conferences, Steven La
Zacks Small Cap ResearchAEMD: Positive Results in a Range of Conditions, Including COVID-19 & Monkey Pox
By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Expanding the Potential Indications for Hemopurifier Treatment Aethlon Medical’s (NASDAQ:AEMD) clinical trials are moving forward and expanding, as AEMD continues to demonstrate the effectiveness of its lead product, the Aethlon Hemopurifier®, in a broad range of viruses and conditions in single patient emergency use cases and in in vitro
- Simply Wall St.
Aethlon Medical, Inc. (NASDAQ:AEMD) Is About To Turn The Corner
With the business potentially at an important milestone, we thought we'd take a closer look at Aethlon Medical, Inc.'s...
Insider Monkey10 Healthcare and Biotech Stocks to Buy Amid Monkeypox Threat
In this article, we will look at 10 healthcare and biotech stocks to buy amid the monkeypox threat. If you want to explore similar healthcare and biotech stocks, you can also take a look at 5 Healthcare and Biotech Stocks to Buy Amid Monkeypox Threat. In May of 2022, the first case of the monkeypox […]
BenzingaAethlon Medical To Start Lab Studies For Hemopurifier For Monkeypox
Aethlon Medical Inc (NASDAQ: AEMD) said it is commissioning a new in vitro binding experiment to confirm that the Hemopurifier effectively captures the current strain of the monkeypox virus. The Hemopurifier is an extracorporeal (i.e., outside of the body) blood filtration device designed to selectively remove harmful particles from the circulatory system using lectin affinity agents. In 2008, the company conducted an in vitro study demonstrating that the Hemopurifier effectively bound and remov
- Thomson Reuters StreetEvents
Edited Transcript of AEMD.OQ earnings conference call or presentation 9-Aug-22 8:30pm GMT
Q1 2023 Aethlon Medical Inc Earnings Call
PR NewswireAethlon Medical Announces First Quarter Financial Results and Provides Corporate Update
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its first quarter ended June 30, 2022 and provided an update on recent developments.
PR NewswireAethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 9, 2022
Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its first quarter ended June 30, 2022, at 4:15 p.m. EST on Tuesday, August 9, 2022.
PR NewswireAethlon Medical Announces Publication of Peer-Reviewed Journal Article Describing Hemopurifier Resin Binding of Seven COVID-19 Variants
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced the publication of a peer-reviewed journal article in PLOS ONE. The article, titled "Removal of Clinically Relevant SARS-CoV-2 Variants by An Affinity Resin Containing Galanthus nivalis Agglutinin," contains data demonstrating that the proprietary GNA affinity resin of the Aethlon Hemopurifier® efficiently captur
PR NewswireAethlon Medical Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an amendment to the protocol of its ongoing clinical trial investigating the Aethlon Hemopurifier® for patients with severe COVID-19. The newly approved protocol amendment eliminates the inclusion criteria that patients must have a dialysis catheter in
PR NewswireAethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2022 and provided an update on recent developments.